{"id":28176,"date":"2023-05-02T19:09:22","date_gmt":"2023-05-02T23:09:22","guid":{"rendered":"https:\/\/nephcure.org\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/"},"modified":"2024-05-01T16:28:19","modified_gmt":"2024-05-01T20:28:19","slug":"travere-therapy-anuncia-los-resultados-del-estudio-duplex-en-fsgs","status":"publish","type":"post","link":"https:\/\/nephcure.org\/es\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/","title":{"rendered":"Travere Therapeutics anuncia los resultados del estudio DUPLEX en FSGS"},"content":{"rendered":"<p style=\"font-weight: 400;\">KING OF PRUSSIA, Pensilvania (2 DE MAYO DE 2023) \u2013 Travere Therapeutics anunci\u00f3 el lunes los resultados de su estudio DUPLEX de fase 3, que prueba el f\u00e1rmaco sparsentan en pacientes con glomeruloesclerosis focal y segmentaria (FSGS). Si bien el estudio DUPLEX no logr\u00f3 su objetivo principal de evaluaci\u00f3n de la TFGe, los resultados de sus variables secundarias son alentadores.<\/p>\n<p style=\"font-weight: 400;\">Al final del estudio de 108 semanas de duraci\u00f3n, la pendiente total de la TFGe en comparaci\u00f3n con el f\u00e1rmaco de control, irbesart\u00e1n, no alcanz\u00f3 sus objetivos de mostrar significaci\u00f3n estad\u00edstica. Sin embargo, los resultados tambi\u00e9n mostraron:<\/p>\n<ul>\n<li>Una reducci\u00f3n promedio de 50% en la proteinuria durante el tratamiento.<\/li>\n<li>Tasa de remisi\u00f3n m\u00e1s del doble: 18% de pacientes que recibieron sparsentan lograron una remisi\u00f3n completa, frente a solo 7% que recibieron irbesart\u00e1n.<\/li>\n<\/ul>\n<p style=\"font-weight: 400;\">Los resultados del estudio DUPLEX tambi\u00e9n indicaron que sparsesentan fue bien tolerado, con un perfil de seguridad consistente comparable al de irbesart\u00e1n. Adem\u00e1s, los pacientes informaron anecd\u00f3ticamente una reducci\u00f3n del edema (m\u00e1s informaci\u00f3n sobre esto se publicar\u00e1 a medida que se publiquen datos adicionales).<\/p>\n<p style=\"font-weight: 400;\">\u201cLa FSGS es una forma particularmente agresiva de enfermedad renal para la que actualmente no existe ning\u00fan tratamiento aprobado por la FDA. Existe una gran necesidad insatisfecha de opciones de tratamiento para los afectados por GEFS. Garantizar que los pacientes tengan opciones sobre los medicamentos que toman es de suma importancia\u201d, dijo Josh Tarnoff, director ejecutivo de NephCure. &quot;NephCure siempre ha enfatizado la importancia de detener la enfermedad y reducir las prote\u00ednas en la orina, y el sparsesentan est\u00e1 demostrando que lo hace bas\u00e1ndose en estos resultados&quot;.<\/p>\n<p style=\"font-weight: 400;\">Seg\u00fan Travere Therapeutics, la compa\u00f1\u00eda continuar\u00e1 explorando un posible camino a seguir con la FDA para un <a href=\"https:\/\/www.fda.gov\/drugs\/types-applications\/new-drug-application-nda\">Solicitud de nuevo medicamento (NDA)<\/a>. Para obtener m\u00e1s informaci\u00f3n sobre los resultados del estudio DUPLEX, <a href=\"https:\/\/ir.travere.com\/news-releases\/news-release-details\/travere-therapeutics-announces-topline-results-two-year-primary\" target=\"_blank\" rel=\"noopener\">Lea el comunicado de prensa de Travere aqu\u00ed.<\/a><\/p>\n<p style=\"font-weight: 400;\">Para ver una lista completa de ensayos cl\u00ednicos en el espacio de enfermedades renales raras, visite <a href=\"http:\/\/kidneyhealthgateway.com\/\">KidneyHealthGateway.com<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>KING OF PRUSSIA, Pensilvania (2 DE MAYO DE 2023) \u2013 Travere Therapeutics anunci\u00f3 el lunes los resultados de su estudio DUPLEX de fase 3, que prueba el f\u00e1rmaco sparsentan en pacientes con glomeruloesclerosis focal y segmentaria (FSGS). \u2026 <a title=\"Travere Therapeutics anuncia los resultados del estudio DUPLEX en FSGS\" class=\"read-more\" href=\"https:\/\/nephcure.org\/es\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/\" aria-label=\"Leer m\u00e1s sobre Travere Therapeutics anuncia los resultados del estudio DUPLEX en FSGS\">Leer m\u00e1s<\/a><\/p>","protected":false},"author":222,"featured_media":28165,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[354],"tags":[],"disease-category":[],"resource-type":[260],"treatment-option":[],"hf_cat_post":[],"class_list":["post-28176","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recent-news","resource-type-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.1 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Travere Therapeutics Announces Results from DUPLEX Study in FSGS - NephCure<\/title>\n<meta name=\"description\" content=\"KING OF PRUSSIA, Pa. (MAY 2, 2023) \u2014 Travere Therape\u00ad\u00adutics announced Monday results from their Phase 3 DUPLEX Study, which tests the drug sparsentan in - Read more about Travere Therapeutics Announces Results from DUPLEX Study in FSGS on NephCure.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nephcure.org\/es\/travere-therapy-anuncia-los-resultados-del-estudio-duplex-en-fsgs\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Travere Therapeutics Announces Results from DUPLEX Study in FSGS\" \/>\n<meta property=\"og:description\" content=\"KING OF PRUSSIA, Pa. (MAY 2, 2023) \u2014 Travere Therape\u00ad\u00adutics announced Monday results from their Phase 3 DUPLEX Study, which tests the drug sparsentan in - Read more about Travere Therapeutics Announces Results from DUPLEX Study in FSGS on NephCure.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nephcure.org\/es\/travere-therapy-anuncia-los-resultados-del-estudio-duplex-en-fsgs\/\" \/>\n<meta property=\"og:site_name\" content=\"NephCure\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/nephcure\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-02T23:09:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-01T20:28:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/Untitled-design-74.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1890\" \/>\n\t<meta property=\"og:image:height\" content=\"1890\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Lauren Eva\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@nephcure\" \/>\n<meta name=\"twitter:site\" content=\"@nephcure\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lauren Eva\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\\\/\"},\"author\":{\"name\":\"Lauren Eva\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/#\\\/schema\\\/person\\\/434bf0351b94952973f03e725afea9b7\"},\"headline\":\"Travere Therapeutics Announces Results from DUPLEX Study in FSGS\",\"datePublished\":\"2023-05-02T23:09:22+00:00\",\"dateModified\":\"2024-05-01T20:28:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\\\/\"},\"wordCount\":286,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Untitled-design-74.png\",\"articleSection\":[\"Recent News\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nephcure.org\\\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\\\/\",\"url\":\"https:\\\/\\\/nephcure.org\\\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\\\/\",\"name\":\"Travere Therapeutics Announces Results from DUPLEX Study in FSGS - NephCure\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Untitled-design-74.png\",\"datePublished\":\"2023-05-02T23:09:22+00:00\",\"dateModified\":\"2024-05-01T20:28:19+00:00\",\"description\":\"KING OF PRUSSIA, Pa. (MAY 2, 2023) \u2014 Travere Therape\u00ad\u00adutics announced Monday results from their Phase 3 DUPLEX Study, which tests the drug sparsentan in - Read more about Travere Therapeutics Announces Results from DUPLEX Study in FSGS on NephCure.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nephcure.org\\\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Untitled-design-74.png\",\"contentUrl\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/Untitled-design-74.png\",\"width\":1890,\"height\":1890},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nephcure.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Travere Therapeutics Announces Results from DUPLEX Study in FSGS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/#website\",\"url\":\"https:\\\/\\\/nephcure.org\\\/\",\"name\":\"NephCure\",\"description\":\"For Rare Kidney Disease\",\"publisher\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nephcure.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/#organization\",\"name\":\"NephCure\",\"url\":\"https:\\\/\\\/nephcure.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/cropped-NephCure-favicon-512x512-1.png\",\"contentUrl\":\"https:\\\/\\\/nephcure.org\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/cropped-NephCure-favicon-512x512-1.png\",\"width\":512,\"height\":512,\"caption\":\"NephCure\"},\"image\":{\"@id\":\"https:\\\/\\\/nephcure.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/nephcure\\\/\",\"https:\\\/\\\/x.com\\\/nephcure\",\"https:\\\/\\\/www.instagram.com\\\/nephcure\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nephcure\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/Nephcure\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nephcure.org\\\/#\\\/schema\\\/person\\\/434bf0351b94952973f03e725afea9b7\",\"name\":\"Lauren Eva\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g\",\"caption\":\"Lauren Eva\"},\"sameAs\":[\"https:\\\/\\\/nephcure.org\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Travere Therapeutics anuncia los resultados del estudio DUPLEX en FSGS - NephCure","description":"KING OF PRUSSIA, Pensilvania (2 DE MAYO DE 2023) \u2014 Travere Therapeutics anunci\u00f3 el lunes los resultados de su estudio DUPLEX de fase 3, que prueba el f\u00e1rmaco sparsentan en - Lea m\u00e1s sobre Travere Therapeutics anuncia los resultados del estudio DUPLEX en FSGS en NephCure.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nephcure.org\/es\/travere-therapy-anuncia-los-resultados-del-estudio-duplex-en-fsgs\/","og_locale":"es_MX","og_type":"article","og_title":"Travere Therapeutics Announces Results from DUPLEX Study in FSGS","og_description":"KING OF PRUSSIA, Pa. (MAY 2, 2023) \u2014 Travere Therape\u00ad\u00adutics announced Monday results from their Phase 3 DUPLEX Study, which tests the drug sparsentan in - Read more about Travere Therapeutics Announces Results from DUPLEX Study in FSGS on NephCure.","og_url":"https:\/\/nephcure.org\/es\/travere-therapy-anuncia-los-resultados-del-estudio-duplex-en-fsgs\/","og_site_name":"NephCure","article_publisher":"https:\/\/www.facebook.com\/nephcure\/","article_published_time":"2023-05-02T23:09:22+00:00","article_modified_time":"2024-05-01T20:28:19+00:00","og_image":[{"width":1890,"height":1890,"url":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/Untitled-design-74.png","type":"image\/png"}],"author":"Lauren Eva","twitter_card":"summary_large_image","twitter_creator":"@nephcure","twitter_site":"@nephcure","twitter_misc":{"Escrito por":"Lauren Eva","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nephcure.org\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/#article","isPartOf":{"@id":"https:\/\/nephcure.org\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/"},"author":{"name":"Lauren Eva","@id":"https:\/\/nephcure.org\/#\/schema\/person\/434bf0351b94952973f03e725afea9b7"},"headline":"Travere Therapeutics Announces Results from DUPLEX Study in FSGS","datePublished":"2023-05-02T23:09:22+00:00","dateModified":"2024-05-01T20:28:19+00:00","mainEntityOfPage":{"@id":"https:\/\/nephcure.org\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/"},"wordCount":286,"commentCount":0,"publisher":{"@id":"https:\/\/nephcure.org\/#organization"},"image":{"@id":"https:\/\/nephcure.org\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/#primaryimage"},"thumbnailUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/Untitled-design-74.png","articleSection":["Recent News"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nephcure.org\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nephcure.org\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/","url":"https:\/\/nephcure.org\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/","name":"Travere Therapeutics anuncia los resultados del estudio DUPLEX en FSGS - NephCure","isPartOf":{"@id":"https:\/\/nephcure.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nephcure.org\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/#primaryimage"},"image":{"@id":"https:\/\/nephcure.org\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/#primaryimage"},"thumbnailUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/Untitled-design-74.png","datePublished":"2023-05-02T23:09:22+00:00","dateModified":"2024-05-01T20:28:19+00:00","description":"KING OF PRUSSIA, Pensilvania (2 DE MAYO DE 2023) \u2014 Travere Therapeutics anunci\u00f3 el lunes los resultados de su estudio DUPLEX de fase 3, que prueba el f\u00e1rmaco sparsentan en - Lea m\u00e1s sobre Travere Therapeutics anuncia los resultados del estudio DUPLEX en FSGS en NephCure.","breadcrumb":{"@id":"https:\/\/nephcure.org\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nephcure.org\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nephcure.org\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/#primaryimage","url":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/Untitled-design-74.png","contentUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2024\/04\/Untitled-design-74.png","width":1890,"height":1890},{"@type":"BreadcrumbList","@id":"https:\/\/nephcure.org\/travere-therapeutics-announces-results-from-duplex-study-in-fsgs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nephcure.org\/"},{"@type":"ListItem","position":2,"name":"Travere Therapeutics Announces Results from DUPLEX Study in FSGS"}]},{"@type":"WebSite","@id":"https:\/\/nephcure.org\/#website","url":"https:\/\/nephcure.org\/","name":"NephCure","description":"Para enfermedades renales raras","publisher":{"@id":"https:\/\/nephcure.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nephcure.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nephcure.org\/#organization","name":"NephCure","url":"https:\/\/nephcure.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nephcure.org\/#\/schema\/logo\/image\/","url":"https:\/\/nephcure.org\/wp-content\/uploads\/2023\/03\/cropped-NephCure-favicon-512x512-1.png","contentUrl":"https:\/\/nephcure.org\/wp-content\/uploads\/2023\/03\/cropped-NephCure-favicon-512x512-1.png","width":512,"height":512,"caption":"NephCure"},"image":{"@id":"https:\/\/nephcure.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/nephcure\/","https:\/\/x.com\/nephcure","https:\/\/www.instagram.com\/nephcure\/","https:\/\/www.linkedin.com\/company\/nephcure\/","https:\/\/www.youtube.com\/user\/Nephcure"]},{"@type":"Person","@id":"https:\/\/nephcure.org\/#\/schema\/person\/434bf0351b94952973f03e725afea9b7","name":"loren eva","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e4c1076de72477cc52d49d263104ba71ffc389f340097af1c564ca5b11a1e21d?s=96&d=mm&r=g","caption":"Lauren Eva"},"sameAs":["https:\/\/nephcure.org"]}]}},"_links":{"self":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/posts\/28176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/users\/222"}],"replies":[{"embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/comments?post=28176"}],"version-history":[{"count":0,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/posts\/28176\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/media\/28165"}],"wp:attachment":[{"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/media?parent=28176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/categories?post=28176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/tags?post=28176"},{"taxonomy":"disease-category","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/disease-category?post=28176"},{"taxonomy":"resource-type","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/resource-type?post=28176"},{"taxonomy":"treatment-option","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/treatment-option?post=28176"},{"taxonomy":"hf_cat_post","embeddable":true,"href":"https:\/\/nephcure.org\/es\/wp-json\/wp\/v2\/hf_cat_post?post=28176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}